ImmunityBio, Inc. (IBRX)
NASDAQ: IBRX · Real-Time Price · USD
7.32
+0.07 (0.97%)
At close: Aug 6, 2026, 4:00 PM EDT
7.33
+0.01 (0.14%)
After-hours: Aug 6, 2026, 7:59 PM EDT

ImmunityBio Revenue

ImmunityBio had revenue of $51.24M in the quarter ending June 30, 2026, with 93.91% growth. This brings the company's revenue in the last twelve months to $165.79M, up 192.92% year-over-year. In the year 2025, ImmunityBio had annual revenue of $113.29M with 668.31% growth.

Revenue (ttm)
$165.79M
Revenue Growth
+192.92%
P/S Ratio
46.79
Revenue / Employee
$239,931
Employees
691
Market Cap
7.76B

Revenue Chart

Revenue History

Fiscal Year EndRevenueChangeGrowth
Dec 31, 2025113.29M98.54M668.31%
Dec 31, 202414.75M14.12M2,270.58%
Dec 31, 2023622.00K382.00K159.17%
Dec 31, 2022240.00K-694.00K-74.30%
Dec 31, 2021934.00K329.00K54.38%
Dec 31, 2020605.00K-1.60M-72.52%
Dec 31, 20192.20M2.16M4,585.11%
Dec 31, 201847.00K2.00K4.44%
Dec 31, 201745.00K1,000.002.27%
Dec 31, 201644.00K-192.00K-81.36%
Dec 31, 2015236.00K-405.00K-63.18%
Dec 31, 2014641.00K41.00K6.83%
Dec 31, 2013600.00K--